Dynavax Technologies | DVAX - Operating Profit


Dynavax Technologies reported $21.27M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
AbbVie USD 4.58B 1.13B Sep/2025
Adma Biologics USD 51.01M 8.21M Sep/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD -1.5B 5.01B Sep/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Bristol-Myers Squibb USD 3.64B 135M Sep/2025
Dynavax Technologies USD 21.27M 10.41M Sep/2025
Gilead Sciences USD 3.51B 810M Sep/2025
Glaxosmithkline GBP 3.76B 1.32B Sep/2025
Merck USD 6.24B 318M Dec/2025
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
Novartis USD 4.5B 363M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
TG Therapeutics USD 29.36M 5.48M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025